CLOs on the Move

Orbus Therapeutics

www.orbustherapeutics.com

 
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Wuhan General Group

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercialises a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands.

Dedicated Phase 1

Dedicated Phase 1 is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Equian

One of our nation’s most pressing challenges is the rising cost and affordability of healthcare. At Equian, our efforts are dedicated to addressing this challenge. We provide solutions that ensure each healthcare interaction is paid accurately and at the lowest possible cost. We have a proven system to reduce healthcare cost through proprietary data analytics coupled with deep domain expertise. Once we have aligned with you and analyzed all of the data, we provide integrated payment integrity solutions that eliminate unnecessary spending.

Anthem

Anthem, Inc., is a provider of health insurance in the United States.

Accountable Healthcare IPA

Accountable Healthcare IPA is a Signal Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.